Arbutus Biopharma Corp

Research Arbutus Biopharma Corp (ABUS) on Bullrun: valuation model: 91.8% undervalued, market cap USD 924.48M, P/E 5.7. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerABUS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal91.8% undervalued
• Market capUSD 924.48M
• P/E5.7
• Financial periodFY2025
• RevenueUSD 14.08M
• Revenue growth128.2%
• Net income-USD 33.50M
• Free cash flow-USD 39.64M

Valuation Snapshot

Bullrun's latest valuation model marks Arbutus Biopharma Corp as 91.8% undervalued; latest market cap is USD 924.48M; P/E is 5.7.

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression;

Frequently asked questions

Is Arbutus Biopharma Corp overvalued or undervalued?

Bullrun's valuation model currently marks Arbutus Biopharma Corp as 91.8% undervalued.

What is Arbutus Biopharma Corp's market cap?

Arbutus Biopharma Corp's market capitalization is USD 924.48M.

What is Arbutus Biopharma Corp's P/E ratio?

Arbutus Biopharma Corp's price-to-earnings (P/E) ratio is 5.7.

What does Arbutus Biopharma Corp do?

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.